BACKGROUND: Folic acid (FA) supplementation reduces neural tube defects (NTDs) by 70%. However, the cause of most NTDs cannot be attributed to folate deficiency, to mutations of genes that encode folate pathway enzymes, and folate receptors (FRs) that mediate cellular folate uptake. Mouse embryos nullizygous for the ortholog of the FRalpha gene have lethal congenital abnormalities that are preventable by administration of folinic acid to the dams. To determine whether antibodies to FRs are similarly teratogenic, we studied a rat model. METHODS: Immunohistochemistry with an antiserum to rat FRs was used to identify the receptors on reproductive tissues and embryos. Gestation day (GD) 8 rats received intraperitoneal injections of antiserum to the FRs, and their embryos were examined 2-9 days later. Some rats received pharmacologic doses of folinic acid or dexamethasone before the antiserum was administered. RESULTS: The FRs are present on oocytes, the oviduct, and uterine epithelial cells, and in the embryo at all stages examined between GD4 and GD15. The antiserum has a dose-related effect on embryo viability and organogenesis. Folinic acid prevented teratogenicity resulting from smaller doses of antiserum, but not that caused by larger doses. Resorption of embryos with the larger doses of the antiserum was prevented by dexamethasone. CONCLUSIONS: FRs are expressed on oocytes, epithelial cells of reproductive organs, and embryonic and extraembryonic tissues. Antiserum to FRs administered to pregnant rats causes embryonic damage. Embryo lethality with smaller doses of antiserum is preventable by administration of folinic acid, while larger doses cause embryo damage by immune-mediated cell lysis, which can be prevented by dexamethasone. Copyright 2003 Wiley-Liss, Inc.
BACKGROUND:Folic acid (FA) supplementation reduces neural tube defects (NTDs) by 70%. However, the cause of most NTDs cannot be attributed to folate deficiency, to mutations of genes that encode folate pathway enzymes, and folate receptors (FRs) that mediate cellular folate uptake. Mouse embryos nullizygous for the ortholog of the FRalpha gene have lethal congenital abnormalities that are preventable by administration of folinic acid to the dams. To determine whether antibodies to FRs are similarly teratogenic, we studied a rat model. METHODS: Immunohistochemistry with an antiserum to rat FRs was used to identify the receptors on reproductive tissues and embryos. Gestation day (GD) 8 rats received intraperitoneal injections of antiserum to the FRs, and their embryos were examined 2-9 days later. Some rats received pharmacologic doses of folinic acid or dexamethasone before the antiserum was administered. RESULTS: The FRs are present on oocytes, the oviduct, and uterine epithelial cells, and in the embryo at all stages examined between GD4 and GD15. The antiserum has a dose-related effect on embryo viability and organogenesis. Folinic acid prevented teratogenicity resulting from smaller doses of antiserum, but not that caused by larger doses. Resorption of embryos with the larger doses of the antiserum was prevented by dexamethasone. CONCLUSIONS: FRs are expressed on oocytes, epithelial cells of reproductive organs, and embryonic and extraembryonic tissues. Antiserum to FRs administered to pregnant rats causes embryonic damage. Embryo lethality with smaller doses of antiserum is preventable by administration of folinic acid, while larger doses cause embryo damage by immune-mediated cell lysis, which can be prevented by dexamethasone. Copyright 2003 Wiley-Liss, Inc.
Authors: Yuqi Dong; Linlin Wang; Yunping Lei; Na Yang; Robert M Cabrera; Richard H Finnell; Aiguo Ren Journal: Birth Defects Res Date: 2018-05-06 Impact factor: 2.344
Authors: Robert M Cabrera; Gary M Shaw; Johnathan L Ballard; Suzan L Carmichael; Wei Yang; Edward J Lammer; Richard H Finnell Journal: J Reprod Immunol Date: 2008-09-18 Impact factor: 4.054
Authors: Na Yang; Linlin Wang; Richard H Finnell; Zhiwen Li; Lei Jin; Le Zhang; Robert M Cabrera; Rongwei Ye; Aiguo Ren Journal: Birth Defects Res A Clin Mol Teratol Date: 2016-05-11
Authors: Kerina J Denny; Christina F Kelly; Vinod Kumar; Katey L Witham; Robert M Cabrera; Richard H Finnell; Stephen M Taylor; Angela Jeanes; Trent M Woodruff Journal: Birth Defects Res A Clin Mol Teratol Date: 2016-02-22
Authors: Kerina J Denny; Angela Jeanes; Kristin Fathe; Richard H Finnell; Stephen M Taylor; Trent M Woodruff Journal: Birth Defects Res A Clin Mol Teratol Date: 2013-09
Authors: Maria Isabel Berrocal-Zaragoza; Joan D Fernandez-Ballart; Michelle M Murphy; Pere Cavallé-Busquets; Jeffrey M Sequeira; Edward V Quadros Journal: Fertil Steril Date: 2008-10-23 Impact factor: 7.329
Authors: Camilla Bille; Dorthe Almind Pedersen; Anne-Marie Nybo Andersen; Maria A Mansilla; Jeffrey C Murray; Kaare Christensen; Johnathan L Ballard; Elizabeth B Gorman; Robert M Cabrera; Richard H Finnell Journal: Pediatr Res Date: 2010-03 Impact factor: 3.756